Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection.
bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, announced implementation of key efficiency measures for its flagship product, CyPath Lung, the Company’s noninvasive test for detection of lung cancer. These improvements are projected to decrease the time required to acquire sample data for analysis by nearly 50% and reduce the cost of sample processing by approximately 60%.
Efficiency measures for its flagship product, CyPath® Lung, are projected to decrease the time required to acquire sample data for analysis by nearly 50% and reduce the cost of sample processing by approximately 60%.
The recent enhancements streamline lab processing and data acquisition workflows, reduce reagent usage, and cut laboratory supply costs—all without changing the test itself, how patient sputum samples are collected and processed, or the method by which data is acquired and analyzed. The improvements are expected to result in a greater than 10% increase in overall throughput and a greater than 25% decrease in unit cost.
“The improvements we are announcing today are a result of a year-long operational analysis of how we could improve CyPath Lung without compromising the test’s high performance and without modification to the test that has been validated by our clinical trial,” bioAffinity Technologies President and CEO Maria Zannes said.
Health Technology Insights: DataFirst, TeleRay Partner to Enhance Virtual Care with AI
CyPath Lung uses flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy. Clinical study results demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters.
“Optimization of CyPath Lung is a key objective for our product development team. Alongside refining our branding, expanding our market and building sales, we evaluated operations to confirm to our shareholders that we are providing a cost-effective, accessible lung cancer diagnostic that meets a global need for earlier diagnosis to improve outcomes and increase patient survival while also reducing healthcare costs,” Zannes said.
Health Technology Insights: The Knowledge Tree Joins Summit Education to Support Mental Health
Zannes highlighted a recent economic impact study, authored by pulmonologists Michael Morris, MD, and Sheila Habib, MD, that showed economic benefit for patients and the healthcare system if CyPath Lung is added to the current standard of care. The study found that an average cost savings of $2,773 per patient would have been achieved in 2022 if CyPath Lung had been part of the standard of care for Medicare patients with a positive lung cancer screening, for a total of $379 million. For privately insured patients, the savings could have reached an average of $6,460 per patient, or $895 million nationwide.
The study, “Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result,” attributes the savings to a reduction in follow-up diagnostic assessments, expensive follow-up procedures and procedure-related complications. “The study by Dr. Morris and Dr. Habib reinforces the broader economic and clinical value of CyPath® Lung within the healthcare landscape,” Zannes said.
Health Technology Insights: AMGA, Wilmington Health Launch Value Care Network Nationwide
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
